- Home
- Automated
- NDF A-Z listing
- Alemtuzumab
A
Alemtuzumab
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
Yes
Summary of Biologics
No
Active ingredient: Alemtuzumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
04/01/2022 Disease-modifying therapies for treating multiple sclerosis
The Ministry of Health’s Drug Advisory Committee has recommended:
Fingolimod 0.25 mg and 0.5 mg capsules for treating adults and children with relapsing-remitting multiple sclerosis, and
Siponimod 0.25 mg and 2 mg tablets for treating adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity.
Subsidy status
[R] Fingolimod 0.25 mg and 0.5 mg capsules and siponimod 0.25 mg and 2 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.
[NR] MAF assistance does not apply to any formulations or strengths of alemtuzumab, cladribine, dimethyl fumarate, interferon beta-1a, natalizumab, ofatumumab or teriflunomide for treating adults or children with any form of multiple sclerosis.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |